Crizanlizumab Side Effects
Medically reviewed by Drugs.com. Last updated on Sep 4, 2023.
Applies to crizanlizumab: intravenous solution.
Serious side effects of crizanlizumab
Along with its needed effects, crizanlizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking crizanlizumab:
More common
- back, joint, or body pain
- chest pain or discomfort
- diarrhea
- difficulty with moving
- fever
- muscle pain or stiffness
- nausea and vomiting
- sore throat
- stomach pain
Less common
Incidence not known
- confusion
- cough
- numbness or tingling in the face, arms, or legs
- trouble walking or speaking
Other side effects of crizanlizumab
Some side effects of crizanlizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
For healthcare professionals
Applies to crizanlizumab: intravenous solution.
General
The most commonly reported adverse reactions have included nausea, arthralgia, back pain, and pyrexia.[Ref]
Other
- Very common (10% or more): Pyrexia (11%)
Gastrointestinal
- Very common (10% or more): Nausea (18%)
- Frequency not reported: Oropharyngeal pain, abdominal pain, diarrhea, vomiting
Musculoskeletal
- Very common (10% or more): Arthralgia (18%), Back pain (15%)
- Frequency not reported: Musculoskeletal chest pain, myalgia
Dermatologic
- Frequency not reported: Pruritus
Genitourinary
- Frequency not reported: Vulvovaginal pruritus
Immunologic
- Common (1% to 10%): Anti-drug antibodies
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and therefore, comparison of the incidence of antibodies with the incidence of antibodies in other studies may be misleading. In a study in patients with sickle cell disease, 0 of 45 patients tested positive for anti-drug antibodies. In a study in healthy subjects 1 of 61 patients tested positive for antidrug antibodies.
Local
- Frequency not reported: Infusion-site extravasation, infusion-site pain, infusion-site swelling
- Postmarketing reports: Infusion-related pain occurring in various locations
There have been postmarketing reports of infusion-related pain occurring in various locations during/within 24 hours of the infusion. Some cases have required hospitalization.
References
1. (2019) "Product Information. Adakveo (crizanlizumab)." Novartis Pharmaceuticals
Frequently asked questions
More about crizanlizumab
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: miscellaneous uncategorized agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Crizanlizumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.